Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Mirum Pharmaceuticals, Inc. (MIRM) reported a Q3 loss of $0.30 per share, which is better than the Zacks Consensus Estimate of a $0.45 loss. This is an improvement from the $0.57 loss per share reported a year ago.
November 12, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals reported a Q3 loss of $0.30 per share, beating the Zacks Consensus Estimate of a $0.45 loss. This marks an improvement from the previous year's $0.57 loss per share.
Mirum Pharmaceuticals' Q3 loss per share was better than expected, which is typically seen as a positive indicator for the stock price. The improvement from the previous year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100